“This new generation of the ArtVentive EOS™ peripheral device represents a significant step forward in the EOS™ technology and design, offering profile reductions, reversibility, enhanced control over deployment and the opportunity to advance into new indications. These advancements allow for the development of devices of varying diameters – with the ability to treat smaller and larger vessel sizes – necessary to meet growing market demands,” stated Leon Rudakov, PhD, President and CTO of ArtVentive. “The first EOS™ Gen II animal study produced excellent clinical results, demonstrating the safety and effectiveness of this advanced embolization therapy.”
ArtVentive Medical Group, Inc. announced that the Company conducted its first animal study of its next generation of the ArtVentive Endoluminal Occlusion System (EOS™ Gen II). The EOS™ is designed for use in the peripheral vasculature and offers immediate and permanent vessel occlusion in arterial and venous settings.